Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome
Insoluble (1,3),(1,6)-beta-D-glucan from bakers yeast are indigestible polysaccharides. Previous studies indicate that the intake of insoluble dietary fiber is strongly associated with reduced risk of type 2 diabetes and cardiovascular disease. However, the mechanisms leading to this phenomenon are largely unknown.
There are close relations between metabolic and inflammatory pathways, and a number of hormones, cytokines, signal proteins, bioactive lipids, and transcription factors have been shown to be involved in both systems.
Beta-D-glucans have been suggested to play a role as so called biological response modifiers. Studies in animals indicate that even small doses of (1,3),(1,6)-beta-D-glucan may have beneficial effects on immune activity, i.e., by reducing the secretion of inflammatory factors.
The investigators hypothesize that the intake of isolated (1,3), (1,6)-beta-D-glucan from bakers yeast improves inflammatory makers and insulin-sensitivity in overweight subjects with increased C-reactive protein concentrations at baseline.
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
|Official Title:||Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome|
- Beta-D-glucan induced changes in inflammatory markers, adipokines, and gut hormones. Changes in insulin-sensitivity. [ Time Frame: 3 days ]
- Altered gene expression in adipose tissue if changes in primary outcome measures are shown. [ Time Frame: 3 days ]
|Study Start Date:||November 2006|
|Study Completion Date:||March 2008|
|Primary Completion Date:||March 2008 (Final data collection date for primary outcome measure)|
capsules containing beta glycan
Dietary Supplement: Beta-D-Glucan
1,5 g Beta-D-Glucan daily
Placebo Comparator: y
capsules containing placebo (waxy maize starch)
Dietary Supplement: placebo
1.5 g waxy maize starch daily
Please refer to this study by its ClinicalTrials.gov identifier: NCT00403689
|German Institute of Human Nutrition, Department of Clinical Nutrition, Potsdam-Rehbrücke|
|Nuthetal, Germany, 14558|
|Principal Investigator:||Martin O Weickert, MD||German Institute of Human Nutrition|
|Study Chair:||Andreas FH Pfeiffer, Prof||German Institute of Human Nutrition|